An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Stopped early · Phase 2

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in participants with early AD.

Key facts

Study ID

NCT03712787

Run by

AbbVie

People needed

364

Starts

2019-03-22

Expected to finish

2021-09-30

Last updated by the study team

2022-09-22

Who can join

Age: 57 and older, up to 88. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All subjects with early AD who complete Study M15-566 (NCT02880956), meet all inclusion criteria, and do not meet any exclusion criteria are eligible for enrollment
• Subject was compliant during participation in Study M15-566 (NCT02880956)
• Subject has an identified, reliable study partner who has frequent contact with the subject and who will provide information as to the subject's cognitive and functional abilities

You may not qualify if…

• The subject has any significant change in his/her medical condition since participation in Study M15-566 (NCT02880956) that could interfere with the subject's participation in Study M15-570, could place the subject at increased risk, or could confound interpretation of study results
• More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-566 (NCT02880956)
• The subject is concurrently enrolled in another interventional clinical study involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)

Where it is running

• Irvine Clinical Research /ID# 204000 — Irvine, California, United States
• Ucsd /Id# 204001 — La Jolla, California, United States
• University of California, San /ID# 204011 — San Francisco, California, United States
• Brain Matters Research /ID# 203957 — Delray Beach, Florida, United States
• Neuropsychiatric Research Center of Southwest Florida /ID# 203956 — Fort Myers, Florida, United States
• Mayo Clinic /ID# 203995 — Jacksonville, Florida, United States
• Synexus Clinical Research US, Inc. /ID# 203992 — Orlando, Florida, United States
• University of South Florida /ID# 204009 — Tampa, Florida, United States
• Synexus Clinical Research US, Inc /ID# 204010 — The Villages, Florida, United States
• Emory University / Emory Brain Health Center /ID# 203999 — Atlanta, Georgia, United States
• NeuroStudies.net, LLC /ID# 204004 — Decatur, Georgia, United States
• Advocate Lutheran General Hospital /ID# 203993 — Park Ridge, Illinois, United States
• Southern IL Univ School of Med /ID# 203952 — Springfield, Illinois, United States
• Indiana University /ID# 203989 — Indianapolis, Indiana, United States
• University of Kansas Medical Center - Alzheimer's Disease Center /ID# 203960 — Fairway, Kansas, United States
• University of Kentucky Chandler Medical Center /ID# 203996 — Lexington, Kentucky, United States
• Massachusetts General Hospital /ID# 203954 — Boston, Massachusetts, United States
• Brigham and Women's Physicians /ID# 204003 — Boston, Massachusetts, United States
• Hattiesburg Clinic /ID# 213435 — Hattiesburg, Mississippi, United States
• Princeton Medical Institute /ID# 203953 — Princeton, New Jersey, United States
• North Shore University Hospital /ID# 203994 — New Hyde Park, New York, United States
• Duke Univ Med Ctr /ID# 203958 — Durham, North Carolina, United States
• Oregon Health and Science University /ID# 203997 — Portland, Oregon, United States
• Keystone Clinical Studies LLC /ID# 213183 — Plymouth Meeting, Pennsylvania, United States
• Banner University of Arizona Medical Center Phoenix /ID# 203959 — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.